🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

522 results for “therapy” Clear

  1. 10-week smoking cessation group therapy combined with NicoDerm CQ

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    phase 3 other completed

    1 trial

  2. 2 cycles induction chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  3. 3-dimensional conformal radiation therapy

    United Therapeutics Europe Ltd

    Head and Neck Cancer

    phase 3 other active

    1 trial

  4. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

    Hoffmann-La Roche

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    phase 3 other active

    1 trial

  5. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  6. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  7. A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's disease.

    COLLEGIUM PHARMACEUTICAL, INC

    Anal or recto-cutaneous or recto-vaginal Crohn-related fistula

    phase 3 other active

    1 trial

  8. A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

    Takeda

    Dravet and Lennox-Gastaut Syndromes

    phase 3 other active

    1 trial

  9. ACTISOUFRE, solution pour pulvérisation nasale/buccale en flacon pressurisé, Actisoufre Placebo

    Laboratoire HRA Pharma

    rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy

    phase 3 small molecule active

    1 trial

  10. APF530

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  11. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  12. Adjuvant Immunomodulatory (IM) Therapy

    Ultragenyx UK Limited

    Mucopolysaccharidosis IIIA

    phase 3 small molecule active

    1 trial

  13. Adjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Total Neoadjuvant Treatment

    phase 3 small molecule active

    1 trial

  14. Adjuvant immunotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  15. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

    LISATA THERAPEUTICS, INC.

    Stage IV Melanoma

    phase 3 mab terminated

    1 trial

  16. BAY 3427080, BAY 3427080 60 mg capsules placebo

    Bayer AG

    Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  17. Balugrastim

    Teva Pharma GmbH

    Chemotherapy-induced Neutropenia

    phase 3 mab completed

    1 trial

  18. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 3 other completed

    1 trial

  19. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior Therapy

    phase 3 other completed

    1 trial

  20. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 3 other completed

    3 trials

  21. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    HCV Negative Status

    phase 3 other completed

    1 trial

  22. Behavior therapy

    United Therapeutics Europe Ltd

    Autism Spectrum Disorder

    phase 3 other active

    1 trial

  23. Brief Strategic Family Therapy (BSFT)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  24. CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.

    AstraZeneca AB

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources